TEZSPIRE achieved its two main goals in the Phase III WAYPOINT study involving patients with chronic rhinosinusitis and nasal polyps.

Basiliximab is a chimeric monoclonal antibody that targets the interleukin-2 receptor (IL-2R) alpha chain, also known as CD25.

Palleon Pharmaceuticals shares findings from the Phase 1/2 GLIMMER-01 study on E-602 combined with Cemiplimab for solid tumor patients at the SITC Annual Meeting.

Deutetrabenazine is a small molecule drug that targets VMAT2 and is used in the treatment of nervous system diseases, congenital disorders, and other diseases.

NextCure presents preclinical findings for LNCB74 and new clinical biomarker results for the NC410 combination at the Society for Immunotherapy of Cancer Annual Meeting.

Casimersen, developed by Sarepta Therapeutics, is an antisense oligonucleotide (AON) designed to target and skip exon 45 of the dystrophin gene.

Dupixent has been authorized in the EU as the first and sole treatment for young children suffering from eosinophilic esophagitis.

Iptacopan is a small molecule drug that targets the complement factor B (CFB) and has been approved for various therapeutic areas.

Hanmi Introduces New Obesity Treatment ‘HM17321’: A Breakthrough in Addressing Muscle Loss Linked to GLP-1.

Avastin, also known as bevacizumab, is a monoclonal antibody developed by Genentech, a subsidiary of Roche.

Minghui Pharmaceutical Reports Positive Early Findings from Phase I Trial of MHB039A, a New Bispecific Antibody Targeting PD-1 and VEGF.

CC-91633 is a novel molecular glue drug that targets CK1α and falls within the therapeutic areas of neoplasms, hemic and lymphatic diseases.